Nanoporous delivery system to treat osteomyelitis and regenerate bone: Gentamicin release kinetics and bactericidal effect

Ahmed El‐Ghannam1,2, Karima Ahmed3, Maha Omran4
1Oral Health Science Center, School of Dentistry, University of Kentucky, Lexington, Kentucky 40506-0700
2Tissue Engineering and Bioactive Materials Laboratory, Center for Biomedical Engineering, The Graduate School, Wenner-Gren Reserach Laboratory, University of Kentucky, Lexington, Kentucky 40506-0070
3Department of Biophysics, Cairo University, Cairo, Egypt
4Department of microbiology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

Tóm tắt

AbstractConventional treatment of osteomyelitis involves the repeated surgical removal of dead bone tissue coupled with repeated irrigation of the wound and prolonged systemic administration of antibiotics. Therapy of bone infections could easily last the rest of the patient's life because of the poor accessibility of the infection site by common systemically administered antibiotics. The objective of the present study is to develop a novel bone bioactive resorbable nanocomposite that can serve as a delivery system for antibiotics. We synthesized three different samples of porous bioactive resorbable silica–calcium phosphate nanocomposite (C3S1, C1S1, and C1S3) that has the ability to provide a sustained release of effective dose of gentamicin for 28 days. Porosity measurements showed that the average pore diameter of C3S1, C1S1, and C1S3 samples is 44.8, 54.4, and 70.9 nm, respectively. Moreover, the silica‐rich composite (C1S3) is characterized by a significantly higher surface area (155.8 m2/g) than the silica‐poor samples (C3S1) (42.9 m2/g). For all samples, the release profile study showed initial burst release followed by a sustained release of gentamicin. The released gentamicin has a strong inhibitory effect on Staphylococcus aureus bacteria. In addition FTIR analysis showed the formation of a biological apatite layer on the material surface after 24 h of immersion in simulated body fluid. Results of the study suggest that the silica–calcium phosphate nanocomposite can serve as a delivery vehicle for gentamicin to treat osteomyelitis and regenerate bone. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater

Từ khóa


Tài liệu tham khảo

Ostermann PA, 1993, The role of local antibiotic therapy in the management of compound fractures, Clin Orthop, 295, 102, 10.1097/00003086-199310000-00015

10.1016/S0195-6701(85)80065-7

10.1002/jor.1100110213

10.1002/jor.1100120517

Itokazu M, 1998, Antibiotic‐loaded porous hydroxyapatite blocks for the treatment of osteomyelitis and postoperative infection. A preliminary report, Bull Hosp Joint Dis, 57, 125

10.1016/S1056-8719(98)00027-6

Rushton N, 1997, Application of local antibiotic therapy, Eur J Surg, 578, 27

Wahing H, 1978, The release of gentamicin from polymethylmethacrylate beads: An experimental and pharmacokinetic study, J Bone Joint Surg [Br], 60, 270

10.2165/00003088-199529010-00005

Nelson CL, 1992, Elution characteristics of gentamicin–PMMA beads after implantation in humans, Orthopedics, 17, 415, 10.3928/0147-7447-19940501-06

Şerbetçi K, 2000, Mechanical and thermal properties of hydroxyapatite‐impregnated bone cement, Turk J Med Sci, 30, 543

10.1002/jbm.820190806

10.1002/jab.770050207

10.1002/jbm.820280803

10.1142/9789814317351_0003

10.1016/0142-9612(95)93583-Y

10.1016/S0142-9612(99)00269-0

10.1016/S0142-9612(00)00438-5

10.1046/j.1525-1594.2000.06517.x

10.1002/1097-4636(20000905)51:3<424::AID-JBM17>3.0.CO;2-E

10.1002/jbm.820260807

Shinto Y, 1992, Calcium hydroxyapatite ceramic used as a delivery system for antibiotics, J Bone Joint Surg, 74, 600, 10.1302/0301-620X.74B4.1320622

Korkusuz F, 1993, Experimental implant‐related osteomyelitis treated by antibiotic–calcium hydroxyapatite ceramic composites, J Bone Joint Surg [Br], 75, 111, 10.1302/0301-620X.75B1.8380599

10.1002/jab.770060304

10.1002/jbm.820290106

10.1208/pt030101

10.1002/(SICI)1097-4636(199910)47:1<18::AID-JBM3>3.0.CO;2-T

10.1016/S0142-9612(00)00436-1

10.1016/S0142-9612(96)00190-1

10.1002/1097-4636(2000)53:4<400::AID-JBM14>3.0.CO;2-Z

10.1016/S0142-9612(96)00108-1

10.1016/S0142-9612(99)00139-8

10.1002/1097-4636(200011)52:2<308::AID-JBM9>3.0.CO;2-6

10.1016/S0142-9612(00)00233-7

10.1016/S0142-9612(99)00066-6

10.1002/1097-4636(200111)57:2<313::AID-JBM1173>3.0.CO;2-E

DucheyneP RadinS SantosE. US Patent Number 5 591 453 (1997).

ThutPD Litkowski LeonardJ Greenspan DavidC. US Patent Number 6 197 342 (2001).

10.1002/jbm.a.30022

10.1016/0142-9612(96)87654-X

10.1016/S0142-9612(98)00199-9

10.1093/jac/48.1.117

10.1093/jac/46.3.423

10.1002/jbm.820240607

10.1002/jbm.820260508

10.1007/BF00703460

White DJ, 2000, Anticalculus effects of a novel, dual‐phase polypyrophosphate dentifrice: Chemical basis, mechanism, and clinical response, J Contemp Dent Pract, 1, 001, 10.5005/jcdp-1-4-59

10.1177/08959374990130011001

10.1007/BF00120381

Miyaji F, 1998, Chemical surface treatment of silicone for inducing its bioactivity, 61

10.1002/(SICI)1097-4636(199901)44:1<12::AID-JBM2>3.0.CO;2-E

10.1111/j.1151-2916.1995.tb08686.x

10.1002/(SICI)1097-4636(199623)33:3<139::AID-JBM3>3.0.CO;2-R

10.1016/j.micromeso.2003.12.012